Abacavir is indicated for:
Population group: both men and women, only adolescents (12 years - 18 years old) , adults (18 - 65 years old)
Abacavir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.
The demonstration of the benefit of abacavir is mainly based on results of studies performed in treatment-naïve adult patients on combination therapy with a twice daily regimen.
Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Screening is also recommended prior to re-initiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. Abacavir should not be used in patients known to carry the HLA-B*5701 allele, unless no other therapeutic option is available in these patients, based on the treatment history and resistance testing.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only infants (40 days - 1 year old) , children (1 year - 12 years old)
Abacavir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection, in infants and children.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Abacavir is contraindicated in the following cases: